Liver-function studies in heart-transplant recipients treated with cyclosporin A.
Cyclosporine (CsA) hepatotoxicity has been reported but has not been studied systematically. This study includes 17 patients undergoing heart transplantation (HTx) and being treated with CsA, azathioprine, and corticosteroids. We assessed liver function in these patients before HTx and during the following month by five biological tests: total bile acids (BA), alkaline phosphatase (AP), gamma-glutamyltransferase (GGT), and total bilirubin in serum, and the aminopyrine breath test (ABT). With these tests we could classify the patients into three groups before HTx: normal (group I), mildly altered (group II), and severely altered (group III) liver function. During CsA therapy we did not observe any changes in any test results except for BA and GGT, and these only in group III. The ABT improved significantly in this group. During kinetic studies in patients without liver dysfunction, we confirmed a direct interference of CsA on BA secretion mechanism, but not the GGT increase, which remains to be explained.
D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000632:Aminopyrine; D001647:Bile Acids and Salts / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001944:Breath Tests; D056486:Chemical and Drug Induced Liver Injury; D003524:Cyclosporins / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D008099:Liver / Q000503:physiopathology*; D008107:Liver Diseases / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D005723:gamma-Glutamyltransferase / Q000097:blood
D001647:Bile Acids and Salts; D003524:Cyclosporins; D000632:Aminopyrine; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D001663:Bilirubin